PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)
Study sponsor: Mesoblast, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2010-12-12Actual
Enrollment · participants63Actual
Source updated2026-03-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.